Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Before Price Controversy, Emflaza Got Easy US Nod With Old But Good Enough Data

Mar 31 2017

• By Bridget Silverman

Related Content

PTC Gambles On Success With <em>Emflaza</em>; Says Price Revision Is Needed

Mar 16 2017

Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate

Mar 08 2017

Emflaza Reviewers

Mar 31 2017

Emflaza's 505(b)(2) Pathway Review: Rare, But With Precedent

Apr 01 2017

Emflaza Clinical Development Timeline

Mar 31 2017

Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears

Dec 23 2016

Marathon's High-Priced Window May Not Stay Open Long

Feb 13 2017

Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'

Dec 28 2016

How To Save A Drug: Iressa’s Return Relied On Consistency Across Totality Of Evidence

Oct 26 2016

Related Companies

Marathon Pharmaceuticals LLC

Sarepta Therapeutics, Inc.

Sanofi

PTC Therapeutics, Inc.

Additional Topics

Drug Approval Standards Regulation Approvals Drug Review Profile BioPharmaceutical

More from Drug Review Profiles

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window